"A twoyear multicenter clinical study with  patients with class IIIIV refractory angina randomized to low and high dose CD cells or placebo has revealed that patients who received either a high or low dose of CD  a member of a family of proteins that have an impact on vascularassociated tissue  cells had a significant reduction in angina frequency over patients who received placebo. The patients who were unresponsive to other treatments were considered to have no other options refractory. The researchers used intramyocardial delivery into the ischemic zone after D mapping to register both electrical and mechanical activities of the left ventricle.  Outcomes from the ACTCMI study a twoyear phase II randomized doubleblind placebocontrolled clinical trial will be published in an upcoming cardiac issue of Cell Transplantation http  There are an increasing number of patients with advanced coronary artery disease that are not amenable to surgical or percutaneous revascularization said study coauthor Dr. Timothy D. Henry of the CedarsSinai Heart Institute. These patients frequently have symptoms after having had standard therapies and are left with limited treatment options. Encouraging early clinical trials suggest that cell therapy is an attractive treatment option for these patients especially trials in which subjects were transplanted with autologous selfdonated CD cells.  CD cells drew the attention of researchers for possible therapeutic testing because recent studies pointed to the importance of CD cell content in the bone marrow of patients with risk factors for coronary artery disease in predicting not only baseline but also future exercise capacity. According to the researchers the study demonstrated that CD cells have the ability to restore the microcirculation and improve myocardial tissue perfusion. All of the  patients participating in the ACTCMI study saw significant improvement in both angina frequency and exercise at  months and a trend toward decreasing major cardiac events. There was also a reduction in angina in the placebo group at six months but the effect was less prominent at  and  months reported the researchers. In addition there was a significant reduction in the time to first hospitalization in celltreated patients with a trend toward reduction in mortality as well. The results of our study are even more provocative given that the outcomes represent the effect of a single treatment wrote the researchers. Recent reports suggest that in patients with recurring symptoms repeated cell administration may replicate the initial positive results. The researchers concluded that for no option patients with class IIIIV angina refractory that was unresponsive to conventional medical therapy and who were not candidates for revascularization injection of CD cells resulted in persistent improvement in angina at two years posttreatment. Contact Timothy D. Henry   S. San Clemente Blvd.  Suite A  Los Angeles CA.  Email henrytcshs.org mailtohenrytcshs.org  Tel   Fax  Citation Henry TD Schaer GL Traverse JH Povisc TJ Davidson C Lee JS Costa MA Bass T Mendelsohn F Fortuin FD Pepine CJ Patel AN Riedel N Junge C Hunt A Kereiakes DJ White C Harrington RA Schatz RA Losordo DW the ACTCMI Investigators. Autologous CD Cell Therapy for Refractory Angina  year Outcomes from the ACTCMI StudyCell Transplant. Appeared or available online May   This study scheduled to be published later this year in a special cardiovascular issue of Cell Transplantation is currently freely available online as an unedited early epub at http_Henry_et_al The CoEditorsinChief for CELL TRANSPLANTATION are at the Department of Neurosurgery and Brain Repair Morsani College of Medicine University of South Florida Tampa FL USA and the Center for Neuropsychiatry China Medical University Hospital TaiChung Taiwan. Contact Paul R. Sanberg at psanberghealth.usf.edu mailtopsanberghealth.usf.edu ShinnZong Lin at shinnzongyahoo.com.tw mailtoshinnzongyahoo.com.tw or Associate Editor Samantha Portis at celltransplantationgmail.com mailtocelltransplantationgmail.com"